腫瘍反応性抗体は,非結合性および自己反応性前体から進化する
Roei D Mazor1, Nachum Nathan2, Amit Gilboa3
1Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel; Department of Biological Regulation, Weizmann Institute of Science, Rehovot 7610001, Israel.
Cell
|March 19, 2022
まとめ
卵巣がんにおける抗体分泌細胞 (ASC) は,腫瘍を標的とする抗体を産生する. ソマティック・ハイパーミューテーション (SHM) は,表面オートアンチゲンに対する抗体抗腫瘍反応を誘発し,がんの診断と治療の可能性を秘めています.
科学分野:
- 免疫学
- 腫瘍学
- 分子生物学
背景:
- 腫瘍の微小環境にある抗体分泌細胞 (ASC) は,様々な癌の予後が良くなる.
- 抗体が腫瘍を標的とする能力 (自己反応性) を獲得するメカニズムは,ほとんど不明である.
- 患者から得られた抗体は 癌の診断と治療に 有望です
研究 の 目的:
- 抗腫瘍抗体の反応性におけるソマティック・ハイパーミューテーション (SHM) の役割を調査する.
- 高度卵巣がん (HGSOC) の腫瘍を標的とする自己抗体の起源と特性を特定する.
- 腫瘍反応性自己抗体の癌治療の可能性を探るため
主な方法:
- HGSOC患者からの腫瘍内ASCの分析
- 患者の腫瘍細胞のIgGコーティングの評価
- ASCの変異とクローン拡張分析
- MMP14のような表面オートアンチゲンを標的にする腫瘍反応性抗体の特徴.
- モノクローナル抗体の ゲルムライン構成への逆転
主要な成果:
- HGSOCにおける患者由来腫瘍細胞は,しばしばIgGでコーティングされた.
- 腫瘍内ASCは変異とクローン拡張を示し,表面オートアンチゲンMMP14を標的とした抗体を産生した.
- 腫瘍結合のためにSHMを必要とする抗体と,固有の生殖系統の自己反応性を持つ抗体の2つのクラスを特定した.
- これらの発見は,腫瘍反応性自己抗体が自然に発生するか,抗原駆動の選択によって進化することを示しています.
結論:
- ソマティック・ハイパーミューテーションは,HGSOCにおける表面オートアンチゲンに対する抗体の抗腫瘍反応を促進する重要なメカニズムである.
- 腫瘍反応性自己抗体は自然に発生するか,抗原主導の進化過程によって発生する.
- これらの自己抗体の起源を理解することで,表面抗原を標的としたがん治療の潜在的応用に関する洞察が得られます.
関連する概念動画
Tumor Immunotherapy
699
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
699
B Cell Activation and Differentiation
7.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
7.8K
Diversity of Antigen Receptors
852
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
852
T Cell Activation and Clonal Selection
6.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
6.7K
Hybridoma Technology
15.5K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.5K
Cytotoxic T Cells-mediated Immune Response
3.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
3.1K


